Intellia Therapeutics Inc buy Guggenheim
Start price
12.05.25
/
50%
€7.88
Target price
12.05.26
€40.09
Performance (%)
50.25%
End price
13.05.26
€11.84
Summary
This prediction ended on 13.05.26 with a price of €11.84. The BUY prediction by Guggenheim for Intellia Therapeutics Inc saw massive gains of 50.25%. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | 4.102% | 4.102% | 21.717% |
| iShares Core DAX® | -1,59 % | 5,03 % | 6,33 % |
| iShares Nasdaq 100 | -4,15 % | -0,13 % | 25,73 % |
| iShares Nikkei 225® | -6,30 % | 0,53 % | 41,38 % |
| iShares S&P 500 | -3,23 % | 0,47 % | 20,45 % |
Comments by Guggenheim for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Guggenheim from $55.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten